Sodium tetradecyl sulfate
|Other names||7-Ethyl-2-methyl-4-hendecanol sulfate sodium salt|
|Main uses||Varicose veins, esophageal varices, spider veins|
|Side effects||Pain, redness, swelling, increased pigmentation, skin breakdown|
|US NLM||Sodium tetradecyl sulfate|
|Chemical and physical data|
|Molar mass||316.43 g·mol−1|
|3D model (JSmol)|
Sodium tetradecyl sulfate (STS), sold under the brand name Sotradecol, is a medication used to treat varicose veins, esophageal varices, and spider veins. It is used during a procedure known as sclerotherapy by injection into a vein.
Common side effects include pain, redness, swelling, increased pigmentation, and skin breakdown. Serious side effects may include pulmonary embolism, stroke, and anaphylaxis. It is an anionic surfactant and detergent which results in inflammation, blood clot formation, and scarring of the vein into which it is injected.
Sodium tetradecyl sulfate was approved for medical use in the United States in 1946. It is relatively low in cost. In the United States 5 doses costs about 330 USD as of 2021. In the United Kingdom this amount costs the NHS about £34.
It is occasionally used for the treatment of stabilisation of joints that regularly dislocate, particularly in patients with Ehlers-Danlos syndrome.
In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold in concentrations of 0.2%, 0.5%, 1.0%, and 3%.
It may be prepared by the aldol condensation of methyl isobutyl ketone and 2-ethylhexanal (which is itself formed by the aldol self-concensation of butyraldehyde), followed by sulfonation of the resulting alcohol.
- Jenkinson HA, Wilmas KM, Silapunt S (November 2017). "Sodium Tetradecyl Sulfate: A Review of Clinical Uses". Dermatologic Surgery. 43 (11): 1313–1320. doi:10.1097/DSS.0000000000001143. PMID 28430735.
- "Sodium Tetradecyl Sulfate Monograph for Professionals". Drugs.com. Retrieved 14 October 2021.
- "Sodium tetradecyl sulfate Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 14 October 2021.
- BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2021. p. 248. ISBN 978-0-85711-369-6.
- Burling F (2019). "Comparison of tetradecyl sulfate versus polidocanol injections for stabilisation of joints that regularly dislocate in an Ehlers-Danlos population". BMJ Open Sport & Exercise Medicine. 5 (1): e000481. doi:10.1136/bmjsem-2018-000481. PMC 6350757. PMID 30792884.
- "Fibro-Vein history and details". Archived from the original on 20 May 2013. Retrieved 22 November 2021.